NEJM (Aug 13, 2020) – Population-level mortality from NSCLC in the United States fell sharply from 2013 to 2016, and survival after diagnosis improved substantially. Our analysis suggests that a reduction in incidence along with treatment advances — particularly approvals for and use of targeted therapies — is likely to explain the reduction in mortality observed during this period.
“The survival benefit for patients with non-small cell lung cancer treated with targeted therapies has been demonstrated in clinical trials, but this study highlights the impact of these treatments at the population level,” said Nadia Howlader, Ph.D., of NCI’s Division of Cancer Control and Population Sciences, who led the study. “We can now see the impact of advances in lung cancer treatment on survival.”
The Best Hospitals Honor Roll highlights 20 hospitals that excel across most or all types of care evaluated by U.S. News. Hospitals received points if they were nationally ranked in the 16 specialties – the more specialties and the higher their rank, the more points they got – and if they were rated high performing in any of the 10 procedures and conditions. The top point-scorers made the Honor Roll.
Dexamethasone, a steroid that appears promising for COVID-19 patients, has a long and storied history in medicine. We talk with experts about its many uses, and explore how it might save lives in this pandemic. Writer, Reporter, Editor, Narrator: Sara Reardon Animator: Donald Pearsall
Boomers Daily 